Review Finds Few Late-Stage Trials on Sleep Outcomes in Parkinson's Disease

A review of late-stage interventional trials registered on ClinicalTrials.gov found a surprisingly limited number of phase III or IV studies with robust sleep outcome measures in elderly patients with Parkinson's disease, revealing a considerable research gap. The analysis, published in BMC Geriatrics in 2026, examined studies reporting sleep-related outcomes in elderly PD populations and highlighted gaps and opportunities that could transform future therapeutic approaches.

Parkinson's disease (PD), a progressive neurodegenerative disorder predominantly affecting older adults, continues to pose significant challenges in clinical management, particularly regarding its non-motor symptoms. Sleep disturbances have emerged as critical factors complicating quality of life and disease prognosis. In PD, sleep disorders encompass a spectrum of manifestations, including insomnia, rapid eye movement (REM) sleep behavior disorder (RBD), excessive daytime sleepiness, and fragmented sleep architecture. These conditions are not merely coexistent but often exacerbate the motor symptoms and cognitive decline inherent to PD, underscoring the importance of their identification and management.

The review involved meticulous extraction and analysis of clinical trial records registered up to early 2026, highlighting studies that explicitly incorporated sleep outcomes as primary or secondary endpoints. The findings uncovered a scarcity of advanced trials focused on sleep outcomes, which contrasts sharply with the high prevalence and debilitating impact of sleep disturbances in PD patients.

The review also highlights the heterogeneity of outcome measures employed across trials, ranging from subjective sleep diaries and questionnaires like the Parkinson's Disease Sleep Scale to objective measures including polysomnography and actigraphy. This variability complicates the comparability of results and the synthesis of evidence needed for clinical guidelines. The authors emphasize the urgent need for standardized, validated sleep assessment tools tailored for PD populations to facilitate more rigorous and clinically relevant trial designs.

When evaluating the types of interventions studied, the review notes that pharmacological approaches dominate the landscape, with dopaminergic agents, melatonin, and hypnotics frequently tested. However, there is an emerging interest in non-pharmacological strategies such as cognitive-behavioral therapy for insomnia (CBT-I), light therapy, and physical exercise, which are gradually gaining attention in trial protocols. The authors advocate for expanded research into integrative treatment paradigms combining pharmacological and behavioral modalities.

The review also scrutinizes the representation of older adults in these trials, a population disproportionately affected by both Parkinson's disease and its sleep complications. A critical finding is that many studies exclude participants above certain age thresholds or those with comorbidities commonly seen in older individuals, thereby limiting generalizability. The authors call for more inclusive trial designs that reflect the real-world demographic and health profiles of PD patients.

The temporal aspects of the analyzed trials reveal another pressing issue: the majority are short-term studies, often extending over weeks to a few months, insufficient to capture the chronic and fluctuating nature of sleep disturbances in Parkinson's disease. Longitudinal studies with extended follow-up periods are indispensable for understanding long-term efficacy, safety, and potential adaptation phenomena.